The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Eli Lilly Eli Lilly is a hot growth stock to buy ... which regulators have approved for diabetes treatment (Mounjaro) and weight loss (Zepbound). At its peak, tirzepatide may be the best-selling drug ...

Eli Lilly and Co. plans to set up a $31 million digital health ... Data for tirzepatide, the chemical compound Lilly sells as ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...